Early occurrence of inspiratory muscle ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Early occurrence of inspiratory muscle weakness in parkinson''s disease
Auteur(s) :
Baille, Guillaume [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Perez, Thierry [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Devos, David [Auteur]
451074|||Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV] (OLD)
Deken, Valerie [Auteur]
Service de Biostatistiques [CHRU Lille]
Defebvre, Luc [Auteur]
451074|||Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV] (OLD)
Moreau, caroline [Auteur]
451074|||Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV] (OLD)
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Perez, Thierry [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Devos, David [Auteur]
451074|||Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV] (OLD)
Deken, Valerie [Auteur]
Service de Biostatistiques [CHRU Lille]
Defebvre, Luc [Auteur]
451074|||Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV] (OLD)
Moreau, caroline [Auteur]
451074|||Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV] (OLD)
Titre de la revue :
PLoS One
Nom court de la revue :
PLoS One
Numéro :
13
Pagination :
e0190400
Date de publication :
2018-01-12
ISSN :
1932-6203
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
In Parkinson's disease (PD), respiratory insufficiency (including functional and muscle disorders) can impact dysarthria and swallowing. Most studies of this topic have been performed retrospectively in populations of ...
Lire la suite >In Parkinson's disease (PD), respiratory insufficiency (including functional and muscle disorders) can impact dysarthria and swallowing. Most studies of this topic have been performed retrospectively in populations of patients with advanced PD. The objective of the present study was to characterize lung function (under off-drug conditions) in early-stage PD patients at baseline and then again two years later. Forty-one early-stage PD patients (mean ± SD age: 61.7 ± 7.7; mean ± SD disease duration: 1.9 ± 1.7 years) were prospectively enrolled and compared with 36 age-matched healthy controls. Neurological evaluations and pulmonary function testing were performed in the off-drug condition at the inclusion visit and then two years later. Pulmonary function testing did not reveal any restrictive or obstructive disorders; at baseline, inspiratory muscle weakness was the only abnormality observed in the PD group (in 53.7% of the patients, vs. 25% in controls; p = 0.0105). The PD patients had a lower mean maximal inspiratory mouth pressure than controls and a lower sniff nasal inspiratory pressure. Two years after the initiation of chronic treatment with antiparkinsonian medications, the maximal inspiratory mouth pressure and the sniff nasal inspiratory pressure tended to be higher. Lastly, overall motor outcomes were not significantly worse in patients with inspiratory muscle weakness than in patients without inspiratory muscle weakness. Inspiratory muscle weakness seems to be common in patients with early-stage PD, and was seen to be stable over a two-year period. Additional long-term follow-up studies are required to specify the impact of this new feature of PD.Lire moins >
Lire la suite >In Parkinson's disease (PD), respiratory insufficiency (including functional and muscle disorders) can impact dysarthria and swallowing. Most studies of this topic have been performed retrospectively in populations of patients with advanced PD. The objective of the present study was to characterize lung function (under off-drug conditions) in early-stage PD patients at baseline and then again two years later. Forty-one early-stage PD patients (mean ± SD age: 61.7 ± 7.7; mean ± SD disease duration: 1.9 ± 1.7 years) were prospectively enrolled and compared with 36 age-matched healthy controls. Neurological evaluations and pulmonary function testing were performed in the off-drug condition at the inclusion visit and then two years later. Pulmonary function testing did not reveal any restrictive or obstructive disorders; at baseline, inspiratory muscle weakness was the only abnormality observed in the PD group (in 53.7% of the patients, vs. 25% in controls; p = 0.0105). The PD patients had a lower mean maximal inspiratory mouth pressure than controls and a lower sniff nasal inspiratory pressure. Two years after the initiation of chronic treatment with antiparkinsonian medications, the maximal inspiratory mouth pressure and the sniff nasal inspiratory pressure tended to be higher. Lastly, overall motor outcomes were not significantly worse in patients with inspiratory muscle weakness than in patients without inspiratory muscle weakness. Inspiratory muscle weakness seems to be common in patients with early-stage PD, and was seen to be stable over a two-year period. Additional long-term follow-up studies are required to specify the impact of this new feature of PD.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
CNRS
Inserm
Institut Pasteur de Lille
Université de Lille
CNRS
Inserm
Institut Pasteur de Lille
Université de Lille
Date de dépôt :
2019-11-27T13:04:16Z
2024-03-27T10:27:45Z
2024-03-27T10:27:45Z
Fichiers
- file.pdf
- Non spécifié
- Accès libre
- Accéder au document